Results of the First Completed Clinical Trial of an iPSC-Derived Product: CYP-001 in Steroid-Resistant Acute GvHD. TCT 2019 Poster.LikeFollowShareShare your feedbackQuestions (0)Post questionYour question will be sent privately to Cynata Therapeutics. The company may choose to make this question public.Start the conversationAsk Cynata Therapeutics a question about this update.DiscoverShare your feedbackDiscover
